publication date: Feb. 14, 2020

NCI Director’s Report

Sharpless addresses three big issues in cancer in 2020:

1. NCI grantees are prime targets for foreign influence,

2. Treatment seems to drive drop in lung cancer deaths,

3. RPG paylines to rise from 8% to 10%

By Matthew Bin Han Ong

The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.

“I think it has to be said that tremendous support, that tremendous success in cancer research recently means that cancer research is commercially valuable,” NCI Director Ned Sharpless said at a virtual meeting of NCI advisors Feb. 11. “Therefore, I think the NCI has been definitely the part of the NIH that’s been most embroiled in these issues.

“More of our fundees are involved than probably any other part of the NIH, because I think this is where the action is for the moment, in terms of commercially developed science.”

Sharpless said NCI is involved in a large number of ongoing investigations at NIH.

“We are working closely with the Office of Extramural Research at the NIH as well as, when need be, other groups, like the FBI,” Sharpless said in the meeting  of the National Cancer Advisory Board.

“I don’t think we’re close to being done with it yet, so there have been very visible examples at a number of academic institutions, related to significant salary and research support from institutions and not disclosing it to the NIH. This has led to some really embarrassing things for those institutions. So, individuals being terminated, large fines have been levied … Continue reading Sharpless addresses three big issues in cancer in 2020

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.